Tandem Diabetes Care Stock News

Tandem Diabetes Care beat earnings -- but only by losing less money than expected -- on Thursday. On the plus side, sales jumped much higher than expected.

Tandem Diabetes (TNDM) outperforms in the first quarter, backed by the demand for both t:slim X2 and the newly launched Tandem Mobi.

The headline numbers for Tandem Diabetes Care (TNDM) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall St

Tandem Diabetes Care, Inc. (TNDM) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.80. This compares to loss of $0.63 per share a year ago.

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its first quarter 2024 results after the financial m

Tandem Diabetes Care is facing economic issues affecting its financial results. The company has the tools to bounce back, including a recently launched device.

Tandem Diabetes (TNDM) seeks to grow its business through the acquisition of products or technologies and investments in businesses.

An analyst upgraded his recommendation on the diabetes care specialist. He now rates it a buy, with potential 11% upside to the current share price.

Tandem Diabetes (TNDM), in 2024, intends to advance its AID algorithm and expand its indications to include people living with Type 2 diabetes.

Tandem Diabetes Care (TNDM) reported earnings 30 days ago. What's next for the stock?

Small cap stocks like those discussed below tend to receive much less attention than their large cap competitors. Shares, which boast a market capitalization between $250 million and $2 billion, remai

Product innovations and strategic progress bode well for Tandem Diabetes (TNDM).

Tandem Diabetes Care, Inc. (TNDM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in

Tandem Diabetes delivered weaker-than-expected Q4 results but followed with strong forward guidance. The company launched four new products in the U.S. last quarter.

Tandem Diabetes (TNDM) reports a higher-than-expected loss in the fourth quarter of 2023.